

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 September 2009 (03.09.2009)(10) International Publication Number
WO 2009/106580 A8(51) International Patent Classification:
G01N 33/569 (2006.01)(21) International Application Number:
PCT/EP2009/052307(22) International Filing Date:
26 February 2009 (26.02.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08152183.3 29 February 2008 (29.02.2008) EP(71) Applicant (for all designated States except US): **Tibotec Pharmaceuticals** [IE/IE]; Eastgate Village, Eastgate, Little Island, Co Cork (IE).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **ROYMANS, Dirk André Emmy** [BE/BE]; Tibotec-Virco Virology BVBA, Generaal De Wittelaan L 11B 3, 2800 Mechelen (BE).
DE BONDT, Hendrik Leon Augusta Jozef [BE/BE];Tibotec-Virco Virology BVBA, Generaal De Wittelaan L 11B 3, 2800 Mechelen (BE). **ARNOULT, Eric Pierre Alexandre** [FR/FR]; 20 rue de l'église, 27100 Le Vaudreuil (FR). **VAN VLIJMEN, Herman** [NL/BE]; Tibotec-Virco Virology BVBA, Generaal De Wittelaan L 11B 3, 2800 Mechelen (BE). **BONFANTI, Jean-François** [FR/FR]; 11 Impasse des Lauriers, F-27430 Andé (FR).(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco Comm. VA, J & J Patent Law Department, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,

[Continued on next page]

(54) Title: METHOD FOR IDENTIFYING INHIBITORS AGAINST VIRUSES THAT USE A CLASS I FUSION PROTEIN



(57) Abstract: The invention concerns the generation of a three dimensional model of the six helix bundle (6HB) complexed with an inhibitor and the use of that model to identify, screen and/or develop inhibitors against viruses that use a class I fusion protein. Such inhibitors of viruses that use a class I fusion protein may be effective for treating, for example, respiratory infections by Respiratory Syncytial Virus (RSV).

Figure 2. Schematic view of compound Z positioned in the 6HB target site.



SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
— of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

22 October 2009

(15) Information about Correction:

see Notice of 22 October 2009